Hamilton Thorne (OTCMKTS:HTLZF – Get Free Report) and TransMedics Group (NASDAQ:TMDX – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.
Valuation & Earnings
This table compares Hamilton Thorne and TransMedics Group’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|TransMedics Group||$191.82 million||11.89||-$36.23 million||($1.10)||-63.49|
Hamilton Thorne has higher earnings, but lower revenue than TransMedics Group.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TransMedics Group has a consensus price target of $79.83, indicating a potential upside of 14.31%. Given TransMedics Group’s higher possible upside, analysts plainly believe TransMedics Group is more favorable than Hamilton Thorne.
Insider and Institutional Ownership
99.7% of TransMedics Group shares are owned by institutional investors. 6.7% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Hamilton Thorne and TransMedics Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
TransMedics Group beats Hamilton Thorne on 5 of the 8 factors compared between the two stocks.
About Hamilton Thorne
Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. It offers precision laser systems, imaging systems, and other equipment and consumables for the ART and developmental biology research markets. The company also provides test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration; and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services. In addition, it manufactures and distributes products for reproductive medicine, including clinical and laboratory equipment and disposables, as well as complete installations of ART clinics; and bench top incubators, programmable freezers, loggers, alarms, cryo storage, and software systems and sensors for the safe preservation of medical and biological specimens used in ART and cell biology applications. Further, the company offers Cell-Tek Microscope Chamber, a product for controlling temperature, air flow, humidification, and air quality; laminar flow workstations, incubators, and related products; and artificial intelligence enabled CASA software, consumables, and image analysis systems for the ART and laboratory markets, as well as acts as a value-added reseller of a range of capital equipment and consumables. It sells its products and services through a direct sales force in the United States, Germany, France, Australia, Denmark, Spain, and the United Kingdom, as well as through distributors to fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 75 countries. The company is headquartered in Beverly, Massachusetts.
About TransMedics Group
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Receive News & Ratings for Hamilton Thorne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hamilton Thorne and related companies with MarketBeat.com's FREE daily email newsletter.